CIBER

CIBER.jpg

Contact information

Centro de Investigación Médica en Red (CIBER)
Luzma García Piqueres, responsable de Transferencia de TecnologíaHead of Technology Transfer
C/ Monforte de Lemos 3-5. Pabellón 11
Madrid
Madrid
(+34) 911718122
Areas of activities
  • A. Health Biotechnology
    • Areas of activity
      • Biomarkers
      • Stem cells
      • Cell cultures
      • In vitro diagnostics
      • Medical devices
      • Drug delivery
      • Drug development
      • Screening
      • Cellular Therapy
      • Gene Therapy
      • Biomaterials and tissue therapy
      • Transplant
      • Vaccines
    • Therapeutic areas
      • Cardiovascular diseases and circulatory system
      • Genetic and rare diseases
      • Inflammatory diseases
      • Oncology
      • Digestive system and hepatology
      • Respiratory and pulmonary system
      • Metabolic disorders / Endocrinology
  • D. Services
    • Professional services
      • Supplies and materials providers

The aim of the Consorcio Centro de Investigación Biomédica en Red, M.P, CIBER, a public research consortium set up at the initiative of the Instituto de Salud Carlos III (ISCIII), is to further excellence research in Biomedicine and Health Sciences done in the National Health System and in the Science and Technology System.

To this end efforts and interdisciplinary and multi-institutional research are combined with a preferential dedication of financial resources around knowledge networks formed by centres and research groups reporting to different administrations and public and private institutions.

Products and services

One of the main missions of the CIBER is the translation of knowledge, so that the results of research that we generate are developed in protocols, services and products for the improvement of clinical practice and people’s quality of life.

The technology transfer unit thus wishes to offer our researchers and companies, other private institutions and public research centres the capacities of our groups and technologies that they develop by:

  • Licensing and co-development of our technologies.
  • Undertaking clinical assays.
  • Participation in one of our spin offs.
  • Other forms of cooperation.

 

Biotech Sanitaria

Drugs National Companies
Product / Service Type Therapeutic area Development phase
Pharmaceutical compositions for the prevention of Charcot-Marie-Tooth disease Biodrugs/ Drugs Sistema nervioso central R&D
Pharmaceutical composition for use in the treatment of depression Biodrugs/ Drugs Sistema nervioso central R&D
Pharmaceutical composition comprising 5-dodecanolide, its preparation and its use Biodrugs/ Drugs Inmunología R&D
MicroRNA for the treatment of obesity Gene Therapy, Cell Therapy Trastornos metabólicos / Endocrinología R&D
GUT MICROBIOTA COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF A MENTAL DISORDER Biodrugs/ Drugs R&D
Method for precise gene editing of the COL7A1 gene by homologous recombination-based editing Gene Therapy, Cell Therapy Dermatología R&D
GENETICALLY MODIFIED MSCs overexpressing CXCR4-IL10 AS ALTERNATIVE TREATMENT FOR GRAFT versus HOST DISEASE Gene Therapy, Cell Therapy Inmunología Preclinical
Gene editing medicinal product for Epidermolysis Bullosa Gene Therapy, Cell Therapy Dermatología Preclinical
GENE EDITING FOR THE TREATMENT OF EWING’S SARCOMA Gene Therapy, Cell Therapy Oncología R&D
DREAM NEURONAL CALCIUM SENSOR-MODULATING COMPOUNDS, AND THERAPEUTIC USES THEREOF Biodrugs/ Drugs Sistema nervioso central R&D
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS Biodrugs/ Drugs Trastornos metabólicos / Endocrinología R&D
Combined use of biotine and thiamine for prevention and treatment of Hungtington Disease Biodrugs/ Drugs Sistema nervioso central R&D
CARVACROL AS DISINFECTANT AGAINST LEGIONELLA Biodrugs/ Drugs Enfermedades infecciosas R&D
BACTERIOPHAGUE FOR THE PREVENTION AND TREATMENT OF A MENTAL DISORDERS Biodrugs/ Drugs Sistema nervioso central Preclinical
APTAMERS FOR THE TREATMENT OF CONGENITAL AND ACQUIRED NEUTROPENIAS Biodrugs/ Drugs Oncología, Enfermedades genéticas y raras R&D
COMPOUNDS FOR TREATING HELICOBACTER PYLORI AND CAMPYLOBACTER JEJUNI INFECTION Biodrugs/ Drugs Sistema digestivo y hepatología, Enfermedades infecciosas R&D
Pharmaceutical and nutraceutical compositions with a combination of amino acids and its use in diseases characterized by lipid accumulation in tissues Biodrugs/ Drugs Enfermedades cardiovasculares y sistema circulatorio, Sistema genitourinario y riñón, Trastornos metabólicos / Endocrinología Preclinical
Gene Therapy for the treatment of Diamond-Blackfan Anemia Gene Therapy, Cell Therapy Sangre y sistema linfático, Enfermedades genéticas y raras Preclinical
Research Platforms
Product / Service Type Development phase
Bilateral Pupillometry Platform for small Animals Other Preclinical
Newropharma: A Target Other Preclinical
High Performance Computing Enabling Technologies R&D
Preclinical Validation-Bioimaging CRO, CMO, Screening/Drug Discovery Preclinical
Preclinical Validation-Tissue, Biomaterial and Surface Characterization CRO, CMO, Enabling Technologies Preclinical
Diagnostics and Personalised Medicine
Product / Service Type Therapeutic area Development phase
SARS-CoV-2 immunogenic polypeptide, anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments Enfermedades infecciosas, Sistema respiratorio y pulmonar Preclinical
Methods for the measurement of protein C and activated protein C Biomarkers, Diagnostic Inmunología, Enfermedades infecciosas Preclinical